News | May 24, 2024
Taro shareholders approve merger with Sun Pharma
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
The collaboration aims to bolster healthcare entrepreneurship
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
The award recognizes powerful science–industry collaborations for social good
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Subscribe To Our Newsletter & Stay Updated
